SS Innovations International (NASDAQ: SSII) has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, marking a significant step in the global adoption of robotic-assisted cardiac procedures. The program utilizes the SSi Mantra 3.0 surgical robotic system, developed by SS Innovations, and represents a milestone for both the company and the Sri Lankan healthcare sector.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration highlights the company's commitment to expanding the reach of its technology and training local surgeons. According to a recent company video, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the system.
The significance of this launch extends beyond Sri Lanka's borders. SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, indicating a growing global footprint. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These metrics suggest that the SSi Mantra system is gaining traction in international markets and that the launch in Sri Lanka could serve as a catalyst for further expansion in South Asia.
For Sri Lanka, the introduction of robotic cardiac surgery represents a leap forward in medical capabilities. Robotic-assisted procedures typically offer benefits such as smaller incisions, reduced blood loss, and faster recovery times compared to traditional open-heart surgery. By establishing this program, Kings Hospital Colombo is positioning itself as a regional leader in advanced cardiac care, potentially attracting patients from neighboring countries and reducing the need for medical travel abroad.
The next major corporate milestone for SS Innovations is regulatory expansion. The company is pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up significant markets and further validate the technology's safety and efficacy. The successful launch in Sri Lanka could provide valuable clinical data and real-world experience to support these regulatory efforts.
As the company continues to grow, the latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. The development was highlighted in a recent video from SS Innovations, which described the introduction of the program. For more information, please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These risks are detailed in the company's SEC filings, including the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on these forward-looking statements.
